Google
TNYA — TENAYA THERAPEUTICS INC (Healthcare >> Biotechnology)
TNYA FAQ
What is TNYA's ROE?
TENAYA THERAPEUTICS INC reports a Return on Equity (ROE) of -78.17%.
What is TNYA's dividend yield?
TENAYA THERAPEUTICS INC offers a dividend yield of 0.00%.
What is TNYA's Deepscope Quality Score?
Deepscope rates TNYA's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TNYA?
Deepscope's AI Timing Score for TNYA is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TNYA belong to?
TENAYA THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.71
Price
0.02
(3.44%)
Day Change
|
|
|---|
TNYA, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.71 |
| PBV / Sector |
1.49 / 4.71
GOOD
|
| Earning Per Share | -0.37 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
3.52 M
GREAT
|
| Average 1W Daily Value |
2.82 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-10 09:43:16 |
| Symbol | TNYA |
| Name | TENAYA THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 217.00 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 158.00 / 8,889.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Phone: 650 825 6990
Website: https://www.tenayatherapeutics.com
Employees: 70
Sector: Healthcare >> Biotechnology
Description: Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
